HomeCompareHSTO vs VIG

HSTO vs VIG: Dividend Comparison 2026

HSTO yields 10000.00% · VIG yields 1.61%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 HSTO wins by $55137509079256512.00M in total portfolio value
10 years
HSTO
HSTO
● Live price
10000.00%
Share price
$0.02
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$55137509079256512.00M
Annual income
$54,073,795,673,722,890,000,000.00
Full HSTO calculator →
VIG
Vanguard Dividend Appreciation ETF
● Live price
1.61%
Share price
$215.06
Annual div
$3.45
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$32.3K
Annual income
$175.21
Full VIG calculator →

Portfolio growth — HSTO vs VIG

📍 HSTO pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodHSTOVIG
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, HSTO + VIG cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
HSTO pays
VIG pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

HSTO
Annual income on $10K today (after 15% tax)
$850,000.00/yr
After 10yr DRIP, annual income (after tax)
$45,962,726,322,664,450,000,000.00/yr
VIG
Annual income on $10K today (after 15% tax)
$136.50/yr
After 10yr DRIP, annual income (after tax)
$148.93/yr
At 15% tax rate, HSTO beats the other by $45,962,726,322,664,450,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of HSTO + VIG for your $10,000?

HSTO: 50%VIG: 50%
100% VIG50/50100% HSTO
Portfolio after 10yr
$27568754539628256.00M
Annual income
$27,036,897,836,861,443,000,000.00/yr
Blended yield
98.07%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on HSTO right now

HSTO
Analyst Ratings
2
Buy
Consensus: Buy
Altman Z
-29.6
Piotroski
1/9
VIG
No analyst data
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

HSTO buys
0
VIG buys
0
No recent congressional trades found for HSTO or VIG in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricHSTOVIG
Forward yield10000.00%1.61%
Annual dividend / share$2.00$3.45
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$55137509079256512.00M$32.3K
Annual income after 10y$54,073,795,673,722,890,000,000.00$175.21
Total dividends collected$55066727460582336.00M$1.7K
Payment frequencyquarterlyquarterly
SectorStockETF

Year-by-year: HSTO vs VIG ($10,000, DRIP)

YearHSTO PortfolioHSTO Income/yrVIG PortfolioVIG Income/yrGap
1← crossover$1,010,700$1,000,000.00$11,301$160.59+$999.4KHSTO
2$95,539,393$94,457,943.93$12,752$162.91+$95.53MHSTO
3$8,447,007,736$8,344,780,585.66$14,370$165.02+$8446.99MHSTO
4$698,565,746,383$689,527,448,105.17$16,176$166.93+$698565.73MHSTO
5$54,040,711,670,213$53,293,246,321,583.74$18,188$168.67+$54040711.65MHSTO
6$3,910,851,616,519,516$3,853,028,055,032,387.00$20,432$170.25+$3910851616.50MHSTO
7$264,781,167,546,477,440$260,596,556,316,801,570.00$22,933$171.68+$264781167546.45MHSTO
8$16,772,556,223,821,672,000$16,489,240,374,546,942,000.00$25,720$172.98+$16772556223821.65MHSTO
9$994,124,678,068,810,000,000$976,178,042,909,320,800,000.00$28,827$174.15+$994124678068810.00MHSTO
10$55,137,509,079,256,515,000,000$54,073,795,673,722,890,000,000.00$32,288$175.21+$55137509079256512.00MHSTO

HSTO vs VIG: Complete Analysis 2026

HSTOStock

Histogen Inc., a clinical-stage therapeutics company, focuses on developing proprietary hypoxia-generated growth factor technology platform and stem cell-free biologic products. It offers HST-003, a human extracellular matrix, which is in Phase 1/2 clinical trial to treat articular cartilage defects in the knee; HST-004, a cell conditioned media solution to treat spinal disc repair; and Emricasan, an orally active pan-caspase inhibitor for the treatment of COVID-19. The company's preclinical product candidates include CTS-2090 and CTS-2096, which are selective caspase-1 inhibitors targeting inflammasome activation, as well as intervenes in a various inflammation mediated disease. Histogen Inc. was founded in 2007 and is headquartered in San Diego, California.

Full HSTO Calculator →

VIGETF

Seeks to track the performance of the S&P U.S. Dividend Growers Index.Passively managed, full-replication approach.Fund remains fully invested.Large-cap equity, emphasizing stocks with a record of growing their dividends year over year.Low expenses minimize net tracking error.With respect to 75% of its total assets, the fund may not: (1) purchase more than 10% of the outstanding voting securities of any one issuer or (2) purchase securities of any issuer if, as a result, more than 5% of the fund’s total assets would be invested in that issuer’s securities; except as may be necessary to approximate the composition of its target index. This limitation does not apply to obligations of the U.S. government or its agencies or instrumentalities.

Full VIG Calculator →
📬

Get this HSTO vs VIG comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

HSTO vs SCHDHSTO vs JEPIHSTO vs OHSTO vs KOHSTO vs MAINHSTO vs DGROHSTO vs NOBLHSTO vs VYM

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.